Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.

Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.

Webinar presenter Jeffrey Gregg, MD, University of Nevada

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace

General chemistry linearity product, 10/13

Audit MicroControls’ Linearity FD General Chemistry Beckman AU simulates human patient serum samples for determining linearity, calibration verification, and verification of reportable range for albumin, alkaline phosphatase, ALT, total amylase, AST, total bilirubin, direct bilirubin, BUN, calcium, chloride, cholesterol, CO2, creatine kinase, creatinine, gamma-GT, glucose, iron, lactate, LDH, lipase, magnesium, phosphorous, potassium, sodium, total protein, triglycerides, and uric acid. This five-level lyophilized product, packaged as 10 × 5 mL, has a shelf life of two years and open-vial stability of seven days when stored at 2°C to 8°C.

Study evaluates assay for dengue virus infection, 10/13

A new study, conducted by researchers at the John A. Burns School of Medicine, University of Hawaii, and published in the Journal of Microbiology, evaluated the InBios DENV Detect IgM capture ELISA for qualitative detection of IgM antibodies to dengue virus recombinant antigens. Well-characterized clinical serum samples collected from Hawaii, Vietnam, Niue, Singapore, and American Samoa were tested with the InBios ELISA in comparison with an in-house DENV IgM antibody capture (MAC) ELISA. The agreement, sensitivity, and specificity of the InBios assay were 94, 92, and 94 percent, respectively.

Gram-negative blood culture assay to ID and treat sepsis, 10/13

AdvanDx, a provider of molecular diagnostic tests for identifying pathogens that cause critical infections in hospitalized patients, announced the commercial launch of Gram-Negative QuickFISH BC, the third FDA-cleared test in its QuickFISH blood culture pathogen identification platform.

Genetic test panels for inherited cancer, 10/13

GeneDx announced the launch of a comprehensive suite of genetic tests for inherited cancer, including a 26-gene panel for breast and ovarian cancer that includes BRCA1 and BRCA2 and next-generation sequencing-based multi-gene panels for colorectal cancer, pancreatic cancer, and endometrial cancer.

NGS library prep workstation, 10/13

Next-generation sequencing technologies have become faster and more efficient while library preparation remains a bottleneck. Laboratories require high-throughput, high-quality, stable, clinically relevant, and reproducible sample preparations. Solutions to these problems must not only solve time constraints but do so without the human errors associated with manual methods.

Hereditary cancer panel, 10/13

Myriad Genetics’ myRisk Hereditary Cancer is a multi-gene diagnostic test that provides increased sensitivity by analyzing 25 genes associated with eight major cancers, including breast, colorectal, ovarian, endometrial, pancreatic, prostate, gastric, and melanoma.

Each test report will include a genetic test result, a clinical risk report, and a health care management tool based on professional society guidelines, providing clear and actionable information to improve patient care regardless of whether the patient receives a positive or negative test result.

Peltier-cooled incubators, 10/13

Thermo Fisher Scientific’s Peltier-cooled incubators with solid-state Peltier cooling are for biological and genomics laboratory researchers engaged in fruit fly and biochemical oxygen demand research.

Flu A/B and RSV test, 10/13

Abbott will add a new FDA-cleared molecular diagnostic test for detection and differentiation of influenza A and B and respiratory syncytial virus to its infectious disease testing menu. The IMDx Flu A/B and RSV test developed by IntelligentMDx (IMDx) of Cambridge, Mass., is performed on Abbott’s m2000 molecular diagnostics system.

Updated CLSI standard on newborn screening, 10/13

The Clinical and Laboratory Standards Institute has released an updated edition of its standard NBS01-A6 (replaces LA04-A5), “Blood Collection on Filter Paper for Newborn Screening Programs; Approved Standard-Sixth Edition.” This document contains new information and insight for personnel on the essentials of correctly collecting a high-quality specimen, handling the specimen after it has been collected, transporting it to the testing facility, and sorting the residual specimen that remains after laboratory testing.

PermaBlack HRP chromogen, 10/13

Diagnostic BioSystems added a new chromogen to its color spectrum—PermaBlack/HRP. This HRP-based substrate/chromogen system produces a sharply contrasting ebony black stain, which serves as a useful tool in immunohistochemical and in situ hybridization staining procedures.

MARKETPLACE

TRENDING